Skip to main content
SpringerLink
Log in

Memantine approved to treat moderate to severe Alzheimer’s disease

  • Clinical Trials Report
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Reisberg B, Doody R, Stoffler A, et al., for the Memantine Study gnGroup: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003, 348:1333–1341.

    Article  CAS  Google Scholar 

  2. Tariot P, Farlow M, Grossberg, et al., for the Memantine Study Group: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004, 291:317–324.

    Article  CAS  Google Scholar 

  3. Doraiswamy PM: The role of the N-methyl-D-aspartate receptor in Alzheimer’s disease: therapeutic potential. Curr Neurol Neurosci Rep 2003, 3:373–378.

    Article  Google Scholar 

  4. Lipton SA: Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx: J Am Soc Exp NeuroTherapeutics 2004, 101–110.

Download references

Authors
  1. Karen Marder MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marder, K. Memantine approved to treat moderate to severe Alzheimer’s disease. Curr Neurol Neurosci Rep 4, 349–350 (2004). https://doi.org/10.1007/s11910-004-0080-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-004-0080-y

Keywords

Search

Navigation